Clinical Trials Logo

Ocular Hypertension clinical trials

View clinical trials related to Ocular Hypertension.

Filter by:

NCT ID: NCT01528787 Completed - Ocular Hypertension Clinical Trials

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Start date: March 2012
Phase: Phase 2
Study type: Interventional

In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout the study.

NCT ID: NCT01528111 Completed - Ocular Hypertension Clinical Trials

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Start date: March 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2a study is intended to assess the safety, tolerability, and effects on intraocular pressure of two dose levels and two dose frequencies of LX7101 when administered topically in the eyes of patients diagnosed with primary open-angle glaucoma or ocular hypertension.

NCT ID: NCT01525173 Completed - Glaucoma Clinical Trials

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

Start date: January 2012
Phase: Phase 4
Study type: Interventional

This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.

NCT ID: NCT01510145 Completed - Ocular Hypertension Clinical Trials

Efficacy of Changing to TRAVATAN® From Prior Therapy

Start date: February 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® solution without BAK (benzalkonium chloride) after changing from prior latanoprost 0.005% ophthalmic solution monotherapy in subjects with open-angle glaucoma or ocular hypertension due to tolerability issues.

NCT ID: NCT01493427 Completed - Ocular Hypertension Clinical Trials

Efficacy of Changing to TRAVATAN® From Prior Therapy

Start date: December 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.

NCT ID: NCT01493271 Completed - Clinical trials for Hypertension, Glaucoma, Open-Angle

A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of RO5093151 or placebo twice daily. The anticipated time on study treatment is 7 days with the possibility to extend to 28 days.

NCT ID: NCT01491867 Completed - Glaucoma Clinical Trials

Continuous Intraocular Pressure (IOP) Measurement and Ability to Detect Treatment Effect

Start date: December 2011
Phase: N/A
Study type: Interventional

Continuous intraocular pressure (IOP) measurement with a contact lens sensor may provide more information on the drug-related IOP change than 24-hour IOP measurement with Goldmann applanation tonometry (GAT.

NCT ID: NCT01489670 Completed - Ocular Hypertension Clinical Trials

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Start date: September 2011
Phase: N/A
Study type: Observational

This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.

NCT ID: NCT01481077 Completed - Glaucoma Clinical Trials

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Start date: November 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effect of plug placement on the efficacy, safety and duration of effect of the L-PPDS (latanoprost punctal plug delivery system).

NCT ID: NCT01481051 Completed - Glaucoma Clinical Trials

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Start date: November 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and duration of the L-PPDS (latanoprost punctal plug delivery system) at different dose levels.